Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,165,400
  • Shares Outstanding, K 1,634,540
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 0.98
  • Price/Sales 4.27
  • Price/Cash Flow 15.43
  • Price/Book 7.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.91
  • Number of Estimates 6
  • High Estimate 0.93
  • Low Estimate 0.86
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +21.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.93 +0.16%
on 10/23/18
63.69 -21.48%
on 10/09/18
-12.24 (-19.66%)
since 09/21/18
3-Month
49.93 +0.16%
on 10/23/18
63.69 -21.48%
on 10/09/18
-5.87 (-10.50%)
since 07/23/18
52-Week
49.93 +0.16%
on 10/23/18
70.05 -28.61%
on 02/16/18
-13.74 (-21.55%)
since 10/23/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

GILD : 71.24 (-1.52%)
RHHBY : 30.4600 (-0.81%)
BMY : 50.29 (-1.16%)
Watch for Bristol-Myer Sqb to Potentially Rebound After Falling 5.54% Yesterday

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $50.51 to a high of $51.90. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $54.29...

BMY : 50.29 (-1.16%)
Intel (INTC) to Report Q3 Earnings: Is a Beat in Store?

Robust performance from data-centric businesses, acquisition synergies and new deal wins are likely to benefit Intel's (INTC) third-quarter results.

MSFT : 105.93 (-3.37%)
INTC : 44.07 (-2.09%)
XLNX : 72.81 (-2.80%)
BMY : 50.29 (-1.16%)
Shopify (SHOP) to Report Q3 Earnings: Is a Beat in Store?

Shopify's (SHOP) third-quarter results are likely to benefit from focus on developing merchant base, addition of new functionalities, robust partner ecosystem and solid mobile domain.

SHOP : 129.45 (-3.66%)
EBAY : 27.76 (-2.56%)
AMZN : 1,729.15 (-3.36%)
BMY : 50.29 (-1.16%)
Merck (MRK) to Report Q3 Earnings: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.

MRK : 71.74 (-1.14%)
AMGN : 195.27 (-1.39%)
GSK : 40.42 (-0.20%)
BMY : 50.29 (-1.16%)
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.

VRTX : 171.16 (-3.52%)
REGN : 378.94 (-2.28%)
AMGN : 195.27 (-1.39%)
BMY : 50.29 (-1.16%)
Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden greater-than or equal to10 mut/Mb

Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.S.) and European Union (EU) for the ongoing review...

BMY : 50.29 (-1.16%)
BMY vs. LLY: Which Stock Should Value Investors Buy Now?

BMY vs. LLY: Which Stock Is the Better Value Option?

LLY : 109.54 (-2.22%)
BMY : 50.29 (-1.16%)
ServiceNow (NOW) to Report Q3 Earnings: Is a Beat in Store?

ServiceNow's (NOW) third-quarter 2018 results are expected to benefit from growing G2K customer base and rapid penetration in non-ITSM markets.

ELY : 21.64 (-6.44%)
NOW : 174.48 (-2.44%)
MLNX : 70.19 (-2.50%)
BMY : 50.29 (-1.16%)
Is a Beat in Store for Citrix Systems (CTXS) in Q3 Earnings?

Citrix's (CTXS) third-quarter results are expected to benefit from impressive growth in subscription-based services segment and buyout synergies.

CTXS : 101.31 (-1.07%)
ELY : 21.64 (-6.44%)
NOW : 174.48 (-2.44%)
BMY : 50.29 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 52.49
1st Resistance Point 51.68
Last Price 50.29
1st Support Level 50.29
2nd Support Level 49.71

See More

52-Week High 70.05
Fibonacci 61.8% 62.36
Fibonacci 50% 59.99
Fibonacci 38.2% 57.62
Last Price 50.29
52-Week Low 49.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar